A securities class action has been filed in the USDC — E.D.PA. against Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or the “Company”), on behalf of all persons or entities that purchased or otherwise acquired Marinus securities publicly traded on the NASDAQ between March 17, 2021 and May 7, 2024, both dates inclusive (the “Class Period”).

Defendant Marinus describes itself as a “commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone).”

The complaint alleges, defendants made false and/or misleading statements and/or failed to disclose that:

(1) Defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial;

(2) Defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and

(3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times, thereby harming investors.

If you purchased Marinus securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.